Table 2.

Clinical trials in pediatric hematologic malignancies testing RAS pathway inhibitors.

Trial identifier	Study name	Disease	Targeted agent	Class
Hematologic malignancy
NCT03190915	Trametinib in Treating Patients With Relapsed or Refractory Juvenile Myelomonocytic Leukemia	JMML	Trametinib	MEK inhibitor
NCT03705507	International Trial of Selumetinib in Combination With Dexamethasone for the Treatment of Acute Lymphoblastic Leukaemia (SeluDex)	ALL	Selumetinib	MEK inhibitor
NCT03585686	A Combination of Vemurafenib, Cytarabine and 2-chlorodeoxyadenosine in Children With LCH and BRAF V600E Mutation	LCH	Vemurafenib	BRAF inhibitor
Pediatric MATCH
NCT04284774	Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial	Solid Tumors, non-Hodgkin lymphoma, or histiocytic Disorders with HRAS mutations	Tipifarnib	Farnesyltransferase inhibitor
NCT03220035	Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)	Solid Tumors, non-Hodgkin lymphoma, or histiocytic Disorders with BRAF V600E mutations	Vemurafenib	BRAF inhibitor
NCT03213691	Selumetinib Sulfate in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)	Solid Tumors, non-Hodgkin lymphoma, or histiocytic Disorders with MAPK pathway mutations	Selumetinib	MEK inhibitor
NCT03698994	Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)	Solid Tumors, non-Hodgkin lymphoma, or histiocytic Disorders with MAPK pathway mutations	Ulixertinib	ERK inhibitor